Loss of Human Leukocyte Antigen Class I Expression Is Associated with Poor Prognosis in Patients with Advanced Breast Cancer
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Human leukocyte antigen class I (HLA-I) molecules play important roles in regulating immune responses. Loss or reduction of HLA-I expression has been shown to be associated with prognosis in several cancers. Regulatory T-cells (Tregs) also play critical functions in immune response regulation. Evaluation of HLA-I expression status by the EMR8-5 antibody and its clinical impact in breast cancer have not been well studied, and its relationship with Tregs remains unclear. Methods: We evaluated HLA-I expression and Treg infiltration by immunohistochemistry in 465 surgically resected breast cancer samples. We examined the correlation between HLA-I expression and Treg infiltration and clinicopathologic characteristics and survival analyses were performed. Results: Total loss of HLA-I expression was found in 84 breast cancer samples (18.1%). Univariate survival analysis revealed that loss of HLA-I expression was significantly associated with worse disease-specific survival (DSS) (p = .029). HLA-I was not an independent prognostic factor in the entire patient group, but it was an adverse independent prognostic factor for DSS in patients with advanced disease (stage II–IV) (p = .031). Treg numbers were significantly higher in the intratumoral stroma of HLA-I–positive tumors than in HLA-I–negative tumors (median 6.3 cells/high power field vs 2.1 cells/high power field, p < .001). However, Tregs were not an independent prognostic factor in our cohort. Conclusions: Our findings suggest that the loss of HLA-I expression is associated with poor prognosis in breast cancer patients, highlighting the role of HLA-I alterations in immune evasion mechanisms of breast cancer. HLA-I could be a promising marker that enables the application of more effective and precise immunotherapies for patients with advanced breast cancer.
Abstract
Background: Human leukocyte antigen class I (HLA-I) molecules play important roles in regulating immune responses. Loss or reduction of HLA-I expression has been shown to be associated with prognosis in several cancers. Regulatory T-cells (Tregs) also play critical functions in immune response regulation. Evaluation of HLA-I expression status by the EMR8-5 antibody and its clinical impact in breast cancer have not been well studied, and its relationship with Tregs remains unclear. Methods: We evaluated HLA-I expression and Treg infiltration by immunohistochemistry in 465 surgically resected breast cancer samples. We examined the correlation between HLA-I expression and Treg infiltration and clinicopathologic characteristics and survival analyses were performed. Results: Total loss of HLA-I expression was found in 84 breast cancer samples (18.1%). Univariate survival analysis revealed that loss of HLA-I expression was significantly associated with worse disease-specific survival (DSS) (p = .029). HLA-I was not an independent prognostic factor in the entire patient group, but it was an adverse independent prognostic factor for DSS in patients with advanced disease (stage II–IV) (p = .031). Treg numbers were significantly higher in the intratumoral stroma of HLA-I–positive tumors than in HLA-I–negative tumors (median 6.3 cells/high power field vs 2.1 cells/high power field, p < .001). However, Tregs were not an independent prognostic factor in our cohort. Conclusions: Our findings suggest that the loss of HLA-I expression is associated with poor prognosis in breast cancer patients, highlighting the role of HLA-I alterations in immune evasion mechanisms of breast cancer. HLA-I could be a promising marker that enables the application of more effective and precise immunotherapies for patients with advanced breast cancer.
참고문헌 (24)
- Hanahan D, "Hallmarks of cancer : the next generation", Cell, 144, pp.646~674 (2011)
- Aptsiauri N, "MHC class I antigens and immune surveillance in transformed cells", Int Rev Cytol, 256, pp.139~189 (2007)
- Hicklin DJ, "HLA class I antigen downregulation in human cancers : T-cell immunotherapy revives an old story", Mol Med Today, 5, pp.178~186 (1999)
- Garrido F, "Implications for immunosurveillance of altered HLA class I phenotypes in human tumours", Immunol Today, 18, pp.89~95 (1997)
- Madjd Z, "Total loss of MHC class I is an independent indicator of good prognosis in breast cancer", Int J Cancer, 117, pp.248~255 (2005)
- Torigoe T, "Establishment of a monoclonal anti-pan HLA class I antibody suitable for immunostaining of formalin-fixed tissue : unusually high frequency of down-regulation in breast cancer tissues", Pathol Int, 62, pp.303~308 (2012)
- Chang CC, "Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy", J Immunol, 174, pp.1462~1471 (2005)
- de Kruijf EM, "The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer", Clin Cancer Res, 16, pp.1272~1280 (2010)
- Lee HJ, "Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling", Oncotarget, 7, pp.30119~30132 (2016)
- Kaneko K, "Clinical implication of HLA class I expression in breast cancer", BMC Cancer, 11, pp.454~ (2011)
- Lee HJ, "Prognostic significance of tumor-infiltrating lymphocytes and the tertiary lymphoid structures in HER2-positive breast cancer treated with adjuvant trastuzumab", Am J Clin Pathol, 144, pp.278~288 (2015)
- Chung YR, "Prognostic value of tumor infiltrating lymphocyte subsets in breast cancer depends on hormone receptor status", Breast Cancer Res Treat, 161, pp.409~420 (2017)
- Vinay DS, "Immune evasion in cancer:mechanistic basis and therapeutic strategies", Semin Cancer Biol, 35(Suppl), pp.S185~S198 (2015)
- Ishigami S, "Cancerous HLA class I expression and regulatory T cell infiltration in gastric cancer", Cancer Immunol Immunother, 61, pp.1663~1669 (2012)
- Curiel TJ, "Specific recruitment of regulatoryT cells in ovarian carcinoma fosters immune privilege and predicts reduced survival", Nat Med, 10, pp.942~949 (2004)
- deLeeuw RJ, "The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer : a critical review of the literature", Clin Cancer Res, 18, pp.3022~3029 (2012)
- Bates GJ, "Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse", J Clin Oncol, 24, pp.5373~5380 (2006)
- Edge SB, "AJCC cancer staging manual" (2010), Springer
- Allred DC, "Prognostic and predictive factors in breast cancer by immunohistochemical analysis", Mod Pathol, 11, pp.155~168 (1998)
- Liu Y, "Expression of antigen processing and presenting molecules in brain metastasis of breast cancer", Cancer Immunol Immunother, 61, pp.789~801 (2012)
- Tsukahara T, "Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5", Cancer Sci, 97, pp.1374~1380 (2006)
- Gettinger S, "Impaired HLA class I antigen processing and presentation as a mechanism of acquired resistance to immune checkpoint inhibitors in lung cancer", Cancer Discov, 7, pp.1420~1435 (2017)
- Zaretsky JM, "Mutations associated with acquired resistance to PD-1 blockade in melanoma", N Engl J Med, 375, pp.819~829 (2016)
- Del Campo AB, "Adenovirus expressing beta2-microglobulin recovers HLA class I expression and antitumor immunity by increasing T-cell recognition", Cancer Gene Ther, 21, pp.317~332 (2014)